Featuring: publicly traded & venture capital companies on the U.S. (NYSE, NASDAQ, AMEX & OTC: BB) and Canadian (TSX & TSX-V) stock exchanges, Investment & Money Management Ideas. |
|
|
Press Release -
Helix BioPharma Corp. |
|
|
“Our goal is to bring truly unique and exceptional drug products to market, which will thereby distinguish Helix as a leader among its peers and competitors. With each of our two drug development initiatives presently underway, we have products designed to address major unmet medical and market needs. We believe that we represent innovators and leaders in the development of treatments for precancerous cervical lesions and lung adenocarcinomas.” - Donald Segal, Ph.D. (HBP) (Interview published August 31, 2007) |
The Most Powerful Name In Corporate News and Information. |
|
CURRENT ISSUE | COVER ARCHIVES | INDEX | CONTACT | FINANCIALS | MARKETING SERVICES | HOME PAGE |
|
April 7, 2008
WKN: 918 846
NEWS RELEASE
W. THOMAS HODGSON
APPOINTED TO BOARD OF HELIX BIOPHARMA CORP.
(Aurora,
Ontario) – Helix BioPharma Corp. (TSX: HBP /
Frankfurt: WKN 918864)
Helix BioPharma Corp.
today announced that the board of directors has increased the
authorized number of directors from six to seven and has
appointed Mr. W. Thomas Hodgson as director to fill the newly
created position. Mr. Hodgson will also serve as chair of the
three member Audit Committee, replacing Mr. Jack Kay who
previously held the position.
Mr. Hodgson is currently
senior partner and chairman of Greenbrook Capital Partners and
acts as an advisor to the chairman of
Magna Entertainment Corp. Mr. Hodgson’s prior roles
include senior positions with Canadian financial institutions
and U.K. based companies.
Donald Segal, chief
executive officer of Helix BioPharma, said, "Tom's diverse
professional background and capital markets experience will be
an invaluable resource to the board. In addition, his extensive
knowledge of complex financial matters makes him ideally suited
to chair our audit committee. We look forward to his
contributions."
About Helix
BioPharma Corp.
Helix BioPharma Corp. is a biopharmaceutical company
specializing in the field of cancer therapy. The company is
actively developing innovative products for the prevention and
treatment of cancer based on its proprietary technologies.
Helix’s product development initiatives include its Topical
Interferon Alpha-2b and its novel L-DOS47 new drug candidate.
Helix is listed on the TSX under the symbol “HBP” and quoted on
the
Frankfurt,
Berlin,
Munich and
Stuttgart Stock Exchanges under the same symbol.
For
further information
contact:
Investor
Relations
Media Relations
Christina Bessant
David Schull
The
Equicom Group Inc.
Russo Partners LLC
Tel:
(416) 815-0700 ext. 269
Tel:
(212) 845-4271
(800)
385-5451
Fax:
(212) 845-4260
Fax: (416)
815-0080 Email:
David.Schull@russopartnersllc.com
The
Toronto Stock Exchange has not
reviewed and does not accept responsibility for the adequacy or
accuracy of the content of this News Release.
|
|
